Halozyme Therapeutics, Inc. $HALO Shares Sold by Aurora Investment Counsel

Aurora Investment Counsel reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,452 shares of the biopharmaceutical company’s stock after selling 6,583 shares during the period. Aurora Investment Counsel’s holdings in Halozyme Therapeutics were worth $1,193,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Measured Wealth Private Client Group LLC boosted its holdings in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the last quarter. Harbour Investments Inc. boosted its stake in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares during the last quarter. Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 331 shares in the last quarter. Finally, Wexford Capital LP purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth approximately $70,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HALO shares. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $77.81 on Friday. The firm has a market cap of $9.23 billion, a PE ratio of 27.99, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 52 week low of $55.64 and a 52 week high of $82.26. The business’s fifty day simple moving average is $72.03 and its 200-day simple moving average is $70.20.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue was up 42.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 1,923 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 74,102 shares of company stock valued at $5,205,798. Insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.